A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Stevens-Johnson syndrome (SJS) and its severe form, toxic epidermal necrolysis (TEN), are rare but life-threatening cutaneous adverse reactions to drugs, especially to allopurinol, carbamazepine, lamotrigine, phenobarbital, phenytoine, sulfamethoxazole, oxicam and nevirapine. Recently, a strong association between carbamazepine and allopurinol induced SJS or TEN has been described with respectively, HLA-B*1502 and HLA-B*5801 in a Han Chinese population from Taiwan and other Asian countries. OBJECTIVE: The objective is to further investigate the relationship between SJS/TEN and HLA-B in a large number of patients in a European population. METHODS: HLA-B genotyping was performed on 150 patients included in a European study (RegiSCAR) of SJS and TEN. We focused on patients related to 'high-risk' drugs including: 31 cases related to allopurinol, 28 to sulfamethoxazole, 19 to lamotrigine and 14 to oxicam. RESULTS: Sixty-one percent of 31 allopurinol-induced SJS/TEN patients carried the HLA-B*5801 allele and the figure was 55% for 27 patients of European ancestry [odds ratio=80 (34-187)], (P<10(-6)) as previously observed in Han Chinese. For other drugs, two rare alleles showed a weaker association with SJS/TEN in a limited number of patients: B*38 for sulfamethoxazole or lamotrigine-related patients, and B*73 for oxicam. CONCLUSION: At variance with prior results in Asia, this study shows that even when HLA-B alleles behave as strong risk factors, as for allopurinol, they are neither sufficient nor necessary to explain the disease. Further investigations are necessary to delineate the exact role of the HLA region in SJS/TEN, and to look for other associations in other regions of the genome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, several studies have found that HLA-B*58:01, which was expressed relatively more frequently in the Chinese population (10–15%) compared to the Caucasian population (0.8%) is strongly associated with allopurinol sensitivity and cause Stevens–Johnson Syndrome [104].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [104]
In the citing paper
“Furthermore, several studies have found that HLA-B*58:01, which was expressed relatively more frequently in the Chinese population (10–15%) compared to the Caucasian population (0.8%) is strongly associated with allopurinol sensitivity and cause Stevens–Johnson Syndrome [104].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [104]
Citations
Cites
Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies
Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998) · JAMA · doi:10.1001/jama.279.15.1200 · Cited by 4,807 · cited 1×
“Adverse reactions to drugs are important causes of morbidity and even of death in developed countries [ 1 ].”
BackgroundA marker for Stevens–Johnson syndrome
Chung, W.-H., Hung, S.-I., Hong, H.-S., Hsih, M.-S., Yang, L.-C., Ho, H.-C., Wu, J.-Y., & Chen, Y.-T. (2004) · Nature · doi:10.1038/428486a · Cited by 1,753
Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis
Roujeau, J.-C., Kelly, J. P., Naldi, L., Rzany, B., Stern, R. S., Anderson, T., Auquier, A., Bastuji-Garin, S., Correia, O., Locati, F., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332404 · Cited by 1,465
Self-citationMallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07873-x · Cited by 1,380 · cited 1×
“In the previous years growing interest focused on the role of HLA in severe drug reactions, which was initiated by the demonstration that HLA-B*5701, was strongly associated with hypersensitivity to the anti-HIV medication abacavir [ 16 ,17].”
BackgroundHLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
Hung, S.-I., Chung, W.-H., Liou, L.-B., Chu, C.-C., Lin, M., Huang, H.-P., Lin, Y.-L., Lan, J.-L., Yang, L.-C., Hong, H.-S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409500102 · Cited by 1,284 · cited 4×
“In Taiwan the carrier prevalence of B*5801 was 20% in a control group [ 21 ].”
BackgroundInfluentialMockenhaupt, M., Viboud, C., Dunant, A., Naldi, L., Halevy, S., Bavinck, J. N. B., Sidoroff, A., Schneck, J., Roujeau, J.-C., & Flahault, A. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701033 · Cited by 1,017
Self-citationInhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin
Viard, I., Wehrli, P., Bullani, R., Schneider, P., Holler, N., Salomon, D., Hunziker, T., Saurat, J.-H., Tschopp, J., & French, L. E. (1998) · Science · doi:10.1126/science.282.5388.490 · Cited by 1,005 · cited 1×
“The initial events triggering the immune reaction remain to be identified [ 10 ].”
BackgroundInhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
(1999) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(99)80071-6 · Cited by 869
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir
Hetherington, S., Hughes, A. R., Mosteller, M., Shortino, D., Baker, K. L., Spreen, W., Lai, E., Davies, K., Handley, A., Dow, D. J., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08158-8 · Cited by 807
Delayed Drug Hypersensitivity Reactions
Pichler, W. J. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-8-200310210-00012 · Cited by 735
Cited by
Items 201–300 of 660
An update on HLA alleles associated with adverse drug reactions
Fricke-Galindo, I., LLerena, A., & López, M. (2017) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmpt-2016-0025 · Cited by 47
Genetics and the Potential for Predictive Tests in Adverse Drug Reactions
Pirmohamed, M. (2012) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000335613 · Cited by 46
Update on pathobiology in Stevens-Johnson syndrome and toxic epidermal necrolysis
Su, S., & Chung, W. (2013) · Dermatologica Sinica · doi:10.1016/j.dsi.2013.09.002 · Cited by 46
Gronich, N., Maman, D., Stein, N., & Saliba, W. (2022) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00661-0 · Cited by 46
“We also confirm the high risk associated with COX-2 inhibitors, sulfonamides, cephalosporines, and carbamazepine, previously reported [12, 22].”
BackgroundResultDrug Induced Hypersensitivity and the HLA Complex
Alfirevic, A., & Pirmohamed, M. (2010) · Pharmaceuticals · doi:10.3390/ph4010069 · Cited by 46
“In contrast to carbamazepine, abacavir hypersensitivity is associated with HLA-B*5701 in patients of all ethnic backgrounds, including Caucasians and Black Africans [39].”
ResultInfluentialRisk factors of allopurinol-induced severe cutaneous adverse reactions in a Thai population
Saksit, N., Tassaneeyakul, W., Nakkam, N., Konyoung, P., Khunarkornsiri, U., Chumworathayi, P., Sukasem, C., Suttisai, S., Piriyachananusorn, N., Tiwong, P., et al. (2017) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000285 · Cited by 46
BREATHNACH, S. M. (2010) · Wiley eBooks · doi:10.1002/9781444317633.ch75 · Cited by 46
Chong, H. Y., Lim, Y. H., Prawjaeng, J., Tassaneeyakul, W., Mohamed, Z., & Chaiyakunapruk, N. (2017) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000319 · Cited by 45
Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles
Fontana, R. J., Li, Y., Phillips, E. J., Saeed, N., Barnhart, H. X., Kleiner, D. E., Hoofnagle, J. H., & the Drug Induced Liver Injury Network (2021) · Liver International · doi:10.1111/liv.14903 · Cited by 45
Pharmacogenetic screening of carbamazepine-induced severe cutaneous allergic reactions
Locharernkul, C., Shotelersuk, V., & Hirankarn, N. (2011) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2010.12.054 · Cited by 45
Fernando, S. L., & Broadfoot, A. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.090401 · Cited by 44
“The HLA-B*5801 allele, in contrast to HLA-B*1502, is more evenly distributed among different ethnic groups(10) (Figure 3B) and hence, associations, albeit weaker, have been found in other ethnic groups such as southern Japanese(21) and in white people (OR 80, CI 34–157).(22) Currently, no recommendation exists for gen…”
Genotyping for Severe Drug Hypersensitivity
Karlin, E., & Phillips, E. J. (2014) · Current Allergy and Asthma Reports · doi:10.1007/s11882-013-0418-0 · Cited by 44
Safety profile of anti-gout agents: an update
Stamp, L. K. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000031 · Cited by 44
Genetic factors in susceptibility to contact sensitivity
Friedmann, P. S., Sánchez-Elsner, T., & Schnuch, A. (2015) · Contact Dermatitis · doi:10.1111/cod.12362 · Cited by 44
PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics
McDonagh, E. M., Thorn, C. F., Callaghan, J. T., Altman, R. B., & Klein, T. E. (2014) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000058 · Cited by 43
HLA-associated Drug Hypersensitivity and the Prediction of Adverse Drug Reactions
Negrini, S., & Becquemont, L. (2017) · Pharmacogenomics · doi:10.2217/pgs-2017-0090 · Cited by 43
Lin, C.-C., Chen, C., Wang, C., Chung, W., & Chung, W. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1740591 · Cited by 43
“In addition to HLA-B*15:02, HLA-A*31:01 allele has been found to be associated with CBZ-induced DRESS but not CBZ-induced SJS/TEN in European and Han Chinese [36].”
BackgroundInfluentialDrug-Induced Hypersensitivity Reactions and Pharmacogenomics: Past, Present and Future
Alfirevic, A., & Pirmohamed, M. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.12 · Cited by 43
Genetics of Hyperuricemia and Gout: Implications for the Present and Future
George, R. L., & Keenan, R. T. (2013) · Current Rheumatology Reports · doi:10.1007/s11926-012-0309-8 · Cited by 43
Pharmacogenomic Advances in the Prediction and Prevention of Cutaneous Idiosyncratic Drug Reactions
Pan, R., Dao, R., Chung, W., & Chung, W. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.683 · Cited by 43
“We first reported the strong pharmacogenomic association between HLA-B*58:01 and allopurinol-SCARs in Han Chinese in 2005 (corrected P 5 4.7 3 10-24, OR 5 580.3, 95% CI 5 34.4–9780.9).37 This correlation was subsequently validated among different populations including Asians and Europeans.34,38–40 We recently reported…”
BackgroundInfluentialProgress in the pharmacotherapy of gout
Sundy, J. S. (2010) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283369014 · Cited by 43
Immune dysregulation increases the incidence of delayed‐type drug hypersensitivity reactions
Naisbitt, D. J., Olsson-Brown, A. C., Gibson, A., Meng, X., Ogese, M. O., Tailor, A., & Thomson, P. (2019) · Allergy · doi:10.1111/all.14127 · Cited by 42
HLA alleles and drug hypersensitivity reactions
Profaizer, T., & Eckels, D. D. (2011) · International Journal of Immunogenetics · doi:10.1111/j.1744-313x.2011.01061.x · Cited by 42
“Wherein, only 15 of 27 (55%) Caucasian patients with allopurinol-induced SJS ⁄ TEN were B*58:01 (Lonjou et al., 2008).”
BackgroundIn Vitro Testing for the Diagnosis of Anticonvulsant Hypersensitivity Syndrome: A Systematic Review
Elzagallaai, A. A., Knowles, S. R., Rieder, M. J., Bend, J. R., Shear, N. H., & Koren, G. (2009) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256336 · Cited by 42
Safety and Efficacy of Allopurinol in Chronic Kidney Disease
Thurston, M. M., Phillips, B. B., & Bourg, C. A. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013504740 · Cited by 41
HLA: A Pharmacogenomics Success Story
Becquemont, L. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.38 · Cited by 41
Lee, E. Y., Copaescu, A. M., Trubiano, J. A., Phillips, E. J., Wolfson, A. R., & Ramsey, A. C. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.09.031 · Cited by 40
Sweileh, W. M. (2017) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-017-0566-8 · Cited by 40
Sheng‐Kai, K., Chung, W., Hsueh, Y., Chen, S., Tokunaga, K., Kinoshita, S., Ma, D. H. K., & Ueta, M. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-317105 · Cited by 40
Lamotrigine-induced severe cutaneous adverse reaction: Update data from 1999–2014
Wang, X.-Q., lv, B., Wang, H.-F., Zhang, X., Yu, S., Huang, X., Zhang, J., Tian, C.-L., & Lang, S.-Y. (2015) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2015.01.016 · Cited by 40
“[25].”
Genetic markers of severe cutaneous adverse reactions
Jung, J., Kim, J.-Y., Park, I., Choi, B. W., & Kang, H. (2018) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2018.126 · Cited by 39
“European [50] SJS/TEN 14/27 (55) 28/1822 (1.”
BackgroundDevarbhavi, H. C., & Raj, S. (2018) · Liver International · doi:10.1111/liv.14004 · Cited by 39
Results of Detailed Investigations Into Stevens-Johnson Syndrome With Severe Ocular Complications
Ueta, M. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-23537 · Cited by 39
Capule, F. R., Tragulpiankit, P., Mahasirimongkol, S., Jittikoon, J., Wichukchinda, N., Alentajan-Aleta, L. T., Barit, J. J. G., Casanova-Gutierrez, J., Cabral‐Lim, L., Reyes, J. P. B., et al. (2020) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0143-8 · Cited by 39
Allopurinol Pharmacogenetics: Assessment of Potential Clinical Usefulness
Zineh, I., Mummaneni, P., Lyndly, J., Amur, S., Grenade, L. A. L., Chang, S. H., Rogers, H. L., & Pacanowski, M. A. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.131 · Cited by 39
Pharmacogenetic considerations in the treatment of psychiatric disorders
Lohoff, F., & Ferraro, T. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903508762 · Cited by 43
“Based on these compelling data, the US FDA issued a blackbox warning in 2007 stating that serious and potentially fatal skin reactions may occur with the administration of CBZ in patients positive for the HLA-B*1502 allele.”
ResultInfluentialHuman leukocyte antigen and idiosyncratic adverse drug reactions
Usui, T., & Naisbitt, D. J. (2016) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2016.11.003 · Cited by 39
HLA-A*31:01 and lamotrigine-induced severe cutaneous adverse drug reactions in a Korean population
Kim, B., Jung, J., Kim, T., Chang, Y., Park, H., Moon, J., Lee, S., Jung, K., Jung, K., Chu, K., et al. (2017) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2017.02.011 · Cited by 39
Pharmacogenomics and Epilepsy: The Road Ahead
Cavalleri, G. L., McCormack, M., Alhusaini, S., Chaila, E. C., & Delanty, N. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.85 · Cited by 38
Pavlos, R. K., White, K. D., Wanjalla, C. N., Mallal, S. A., & Phillips, E. J. (2017) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2017.07.007 · Cited by 38
Chu, M.-T., Chang, W., Pao, S.-C., & Chung, W. (2023) · Biomedicines · doi:10.3390/biomedicines11010177 · Cited by 38
“This association was further replicated and validated among various ethnicities, including European [63,64], Thai [65,66], Japanese [67], Korean [68], and African American [69] (Table 3).”
BackgroundResultGenome-wide association study of serious blistering skin rash caused by drugs
Shen, Y., Nicoletti, P., Floratos, A., Pirmohamed, M., Molokhia, M., Geppetti, P., Benemei, S., Giomi, B., Schena, D., Vultaggio, A., et al. (2011) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.84 · Cited by 38
HLA-B*5701 screening prior to abacavir prescription: Clinical and laboratory aspects
Nolan, D. A. (2009) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360902937817 · Cited by 37
“of European ancestry, of whom 45% were HLAB*5801 negative.(59)”
BackgroundPopulation-based high-throughput toxicity screen of human iPSC-derived cardiomyocytes and neurons
Huang, C. Y., Nicholson, M. W., Wang, J. Y., Ting, C. Y., Tsai, M. H., Cheng, Y. C., Liu, C. L., Chan, D. Z. H., Lee, Y. C., Hsu, C. C., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110643 · Cited by 36
Do, M. D., Phuong, T., Do, A. D., Nguyen, Q. D., Le, N. H., Le, L. G. H., Hoang, V. A., Le, A. N., Le, H. Q., Richette, P., et al. (2020) · Arthritis Research & Therapy · doi:10.1186/s13075-020-02273-1 · Cited by 37
Toxic Epidermal Necrolysis in Pregnancy: Case Report and Review of the Literature
Struck, M. F., Illert, T., Liß, Y., Bosbach, I. D., Reichelt, B., & Steen, M. (2010) · Journal of Burn Care & Research · doi:10.1097/bcr.0b013e3181eed441 · Cited by 36
“The susceptibility to drug hypersensitivity demands a complex predisposition, because responsible HLA alleles are drug specific, phenotype specific, and ethnicity specific.(9) Pregnant patients presenting with SJS/ TEN with an association to certain drugs and infections (mainly human immunodeficiency virus infection)…”
BackgroundGenetic predisposition to adverse drug reactions in the intensive care unit
Empey, P. E. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181de09f8 · Cited by 36
“Interestingly, HLA-B*5801 was absent in some European patients without Asian ancestry who experienced cutaneous reactions (88).”
BackgroundWakamatsu, T. H., Ueta, M., Tokunaga, K., Okada, Y., Loureiro, R. R., Costa, K. A., Sallum, J. M. F., Milhomens, J. A., Inoue, C., Sotozono, C., et al. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.0074 · Cited by 35
Maekawa, K., Nishikawa, J., Kaniwa, N., Sugiyama, E., Koizumi, T., Kurose, K., Tohkin, M., & Saito, Y. (2012) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-11-nt-120 · Cited by 35
Genetic Markers Associated with Cutaneous Adverse Drug Reactions to Allopurinol: A Systematic Review
Jarjour, S., Barrette, M., Normand, V., Rouleau, J. L., Dubé, M., & de Denus, S. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.21 · Cited by 34
“96 (63/3200) – – – – Lonjou et al. (2008) SJS/TEN† 61 (19/31)‡ – – 61 (32–118) <10-8 [3]”
Advances in the Pharmacogenomics of Adverse Drug Reactions
Collins, S. L., Carr, D. F., & Pirmohamed, M. (2015) · Drug Safety · doi:10.1007/s40264-015-0367-8 · Cited by 34
Dao, R., Su, S., & Chung, W. (2015) · Asia Pacific Allergy · doi:10.5415/apallergy.2015.5.2.59 · Cited by 33
Barbaud, A. M., Waton, J., Herbeth, B., Bursztejn, A. ‐., Bollaert, M., Schmutz, J. ‐., Guéant‐Rodriguez, R., Namour, F., Guéant, J., & Aimone‐Gastin, I. (2013) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12130 · Cited by 33
Severe skin reactions: clinical picture, epidemiology, etiology, pathogenesis, and treatment
Paulmann, M., & Mockenhaupt, M. (2019) · Allergo Journal International · doi:10.1007/s40629-019-00111-8 · Cited by 32
“Chinese (100%) as well as European subjects (55%) [45, 51].”
BackgroundSelf-citationThe skin as a metabolic and immune-competent organ: Implications for drug-induced skin rash
Sharma, A. M., Saito, Y., Chung, W., Naisbitt, D. J., Uetrecht, J., & Bussiere, J. L. (2018) · Journal of Immunotoxicology · doi:10.1080/1547691x.2018.1514444 · Cited by 32
“These genetic associations were validated in different populations around the world (Lonjou et al. 2008; Tassaneeyakul et al. 2009; McCormack et al. 2011; Genin et al. 2014).”
BackgroundStevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications
Ueta, M. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1729128 · Cited by 31
“For example, allopurinol-induced SJS/TEN was reported to be strongly associated with HLA-B* 58:01 in Han Chinese- [20], Caucasian- [21], and Japanese patients [22].”
BackgroundGenetics of Severe Cutaneous Adverse Reactions
Yang, S.-C., Chen, C., Lin, M., Zhang, Z.-Y., Jia, X., Huang, M. Y., Zou, Y., & Chung, W. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.652091 · Cited by 31
Tangamornsuksan, W., & Lohitnavy, M. (2018) · The Pharmacogenomics Journal · doi:10.1038/s41397-018-0052-2 · Cited by 31
Genomic Risk Factors Driving Immune-Mediated Delayed Drug Hypersensitivity Reactions
Li, Y., Deshpande, P., Hertzman, R. J., Palubinsky, A. M., Gibson, A., & Phillips, E. J. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.641905 · Cited by 31
Teoh, L., Moses, G., & McCullough, M. J. (2019) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12910 · Cited by 30
Yokose, C., Lu, N., Xie, H. W., Li, L., Zheng, Y., McCormick, N., Rai, S. K., Aviña-Zubieta, J. A., & Choi, H. K. (2019) · Canadian Medical Association Journal · doi:10.1503/cmaj.190339 · Cited by 30
Bergmann, M. M., & Caubet, J. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191107104126 · Cited by 30
Tsuchiya, N., Narita, S., Inoue, T., Hasunuma, N., Numakura, K., Horikawa, Y., Satoh, S., Notoya, T., Fujishima, N., Hatakeyama, S., et al. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32835c401c · Cited by 30
HLA Pharmacogenetic Markers of Drug Hypersensitivity in a Thai Population
Nakkam, N., Konyoung, P., Kanjanawart, S., Saksit, N., Kongpan, T., Khaeso, K., Khunarkornsiri, U., Dornsena, A., Tassaneeyakul, W., & Tassaneeyakul, W. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00277 · Cited by 29
Park, H., Kim, D. K., Kim, S., Kim, S., Chae, D., Yang, M., Oh, Y. K., Lee, J. P., Jung, J., Shin, J., et al. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.12.012 · Cited by 29
Mockenhaupt, M. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3408 · Cited by 29
“For this allele an association of 55% was found in allopurinolinduced EN cases of European descent (66).”
BackgroundSelf-citationPrediction of Severe Adverse Drug Reactions Using Pharmacogenetic Biomarkers
Tohkin, M., Ishiguro, A., Kaniwa, N., Saito, Y., Kurose, K., & Hasegawa, R. (2010) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.25.122 · Cited by 29
Updates in the pathogenesis of SJS/TEN
Justice, J., Mukherjee, E. M., Martin‐Pozo, M., & Phillips, E. (2025) · Allergology International · doi:10.1016/j.alit.2025.05.002 · Cited by 28
Pratoomwun, J., Thomson, P., Jaruthamsophon, K., Tiyasirichokchai, R., Jinda, P., Rerkpattanapipat, T., Tassaneeyakul, W., Nakkam, N., Rerknimitr, P., Klaewsongkram, J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658593 · Cited by 28
“As T cells are thought to be involved in the molecular pathogenesis of many forms of severe cutaneous adverse reactions (10–12), a global TCR repertoire analysis in HLA-B*15:02 positive patients with carbamazepine-induced SJS/TEN was studied and clearly demonstrated that restricted TCR usage of drug-specific T cells p…”
BackgroundImpact of New Genomic Technologies on Understanding Adverse Drug Reactions
Maggo, S. D. S., Savage, R. L., & Kennedy, M. A. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0324-9 · Cited by 28
“Sulfomethoxazole [161] HLA-B*3802 SJS 76”
Allopurinol for the treatment of chronic kidney disease: asystematic review
Fleeman, N., Pilkington, G., Dundar, Y., Dwan, K. M., Boland, A., Dickson, R., Anijeet, H. K. I., Kennedy, T., & Pyatt, J. R. (2014) · Health Technology Assessment · doi:10.3310/hta18400 · Cited by 28
Genetic Predisposition to Stevens–Johnson Syndrome With Severe Ocular Surface Complications
Ueta, M. (2015) · Cornea · doi:10.1097/ico.0000000000000605 · Cited by 28
Pharmacogenomics and adverse drug reactions: Primetime and not ready for primetime tests
Khan, D. A. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.08.002 · Cited by 28
“Like the association of carbamazepine-induced SCARs and HLA-B*1502, ethnic differences have been seen, with strong associations in Thai populations with HLA-B*5801 and allopurinol-related SCARs yet weaker but significant associations in European and Japanese populations.(114-116) A study from Australia similarly found…”
ResultPharmacogenomics in Asia: A Systematic Review on Current Trends and Novel Discoveries
Ang, H. X., Chan, S. L., Sani, L. L., Quah, C. B., Brunham, L. R., Tan, B. O. P., & Winther, M. D. (2017) · Pharmacogenomics · doi:10.2217/pgs-2017-0009 · Cited by 28
Clinical manifestations and genetic influences in sulfonamide-induced hypersensitivity
Asyraf, P. A., Kusnadi, I. F., Stefanus, J., Khairinisa, M. A., & Abdulah, R. (2022) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s347522 · Cited by 27
“The risk of this hypersensitivity depends on the structure of the drug, the patient’s immune system, the dose of the drugs, the route of administration, the duration of treatment, and the specific type of HLA.32 A rash is an area of skin that is irritated or swollen.”
BackgroundInfluentialGenetic variants associated with severe cutaneous adverse drug reactions induced by carbamazepine
Nakkam, N., Konyoung, P., Amornpinyo, W., Saksit, N., Tiamkao, S., Khunarkornsiri, U., Khaeso, K., Pattanacheewapull, O., Jorns, T. P., Chumworathayi, P., et al. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15022 · Cited by 27
Lebrun‐Vignes, B., & Valeyrie‐Allanore, L. (2014) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2014.10.004 · Cited by 27
Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention
Gerogianni, K., Tsezou, A., & DIMAS, K. S. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0330-3 · Cited by 27
“An association between HLA-B*58:01 and allopurinol-induced SJS/ TEN was also found in Europeans [87].”
BackgroundInfluentialAhmed, A. F., Sukasem, C., Sabbah, M. A., Musa, N., Noor, D. A. M., & Daud, N. A. A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050383 · Cited by 27
“In the European population, a weak association was found between HLA-B*38 and lamotrigine-induced SJS/TEN (OR 80; p < 10–6) [112].”
BackgroundStevens–Johnson syndrome with sulfasalazine treatment: Report of two cases
Tremblay, L., de Chambrun, G. P., Vroey, B. D., Lavogiez, C., Delaporte, E., Colombel, J., & Cortot, A. (2011) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2011.03.014 · Cited by 27
Saito, Y., & Abe, R. (2023) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000914 · Cited by 26
Pastrana, L. I. C., Ghannadan, R., Rieder, M. J., Dahlke, E. J., Hayden, M. R., & Carleton, B. (2011) · PubMed · Cited by 26
Wu, Z., Li, X., Huang, R., He, B., & Wang, C. (2025) · Investigational New Drugs · doi:10.1007/s10637-024-01499-z · Cited by 25
“HLA-B *38:01 is linked to cotri-moxazole-induced SJS/TEN [21].”
Ueta, M., Inoue, C., Nakata, M., Sotozono, C., Kim, M. K., Wakamatsu, T. H., Jongkhajornpong, P., Saeed, H. N., Rauz, S., Ma, D. H. K., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1189140 · Cited by 25
“Allopurinol-induced SJS/TEN is strongly associated with HLA-B* 58:01 in Han Chinese (15), Caucasian (16), and Japanese patients (17), although allopurinol tends to induce SJS/TEN with fewer and less severe ocular symptoms (18) than in cases with other culprit drugs.”
BackgroundHLA‐B*5801: utility and cost‐effectiveness in the A sia‐ P acific R egion
Yeo, S. I. (2013) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12050 · Cited by 25
Cheminformatics-aided pharmacovigilance: application to Stevens-Johnson Syndrome
Low, Y., Caster, O., Bergvall, T., Fourches, D., Zang, X., Norén, G. N., Rusyn, I., Edwards, R., & Tropsha, A. (2015) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocv127 · Cited by 25
Hypersensitivity to Antiepileptic Drugs
Ye, Y., Thong, B. Y., & Park, H. (2014) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2014.04.005 · Cited by 25
Konvinse, K. C., Phillips, E. J., White, K. D., & Trubiano, J. A. (2016) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000323 · Cited by 25
Immune mediation of hypersensitivity adverse drug reactions: implications for therapy
Rieder, M. J. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330902933736 · Cited by 25
Lin, C.-W. G., Huang, W., Chao, P., Chen, W., & Hsiao, F. (2019) · International Journal of Clinical Practice · doi:10.1111/ijcp.13316 · Cited by 24
Wu, P., Chen, W., Huang, I., Chen, C., Wang, C., Tai, C., Chung, W., & Chi, C. (2024) · JAMA Dermatology · doi:10.1001/jamadermatol.2024.0210 · Cited by 24
PharmGKB summary: very important pharmacogene information for human leukocyte antigen B
Barbarino, J. M., Kroetz, D. L., Klein, T. E., & Altman, R. B. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000118 · Cited by 24
Update on the Genetic Basis of Drug Hypersensitivity Reactions
Jurado‐Escobar, R., Perkins, J. R., García‐Martín, E., Isidoro‐García, M., Doña, I., Torres, M., & Cornejo-García, J. A. (2017) · Journal of Investigational Allergology and Clinical Immunology · doi:10.18176/jiaci.0199 · Cited by 24
Haddad, C., Sidoroff, A., Kardaun, S. H., Mockenhaupt, M., Creamer, D., Dunant, A., & Roujeau, J. (2013) · Drug Safety · doi:10.1007/s40264-013-0070-6 · Cited by 24
“If studies in the Han Chinese population have demonstrated genetic predisposition with HLA-B*1502 allele for carbamazepinerelated cases [15] and with HLA-B*5801 for allopurinol related cases [16], pharmacogenetic studies in Europe did not conclude that there was any genetic link strong enough to allow prevention in Eu…”
ResultSelf-citationAnalysis of Individual Case Safety Reports of Severe Cutaneous Adverse Reactions in Korea
Kang, M., Sohn, K., Kang, D. Y., Park, H., Yang, M., Lee, J., & Kang, H. (2019) · Yonsei Medical Journal · doi:10.3349/ymj.2019.60.2.208 · Cited by 23
“However, the allele frequency of HLA-B*58:01 is lower in Japanese (1–2%)(16) and Caucasians (1–6%).(17) Carbamazepine-induced SCAR is also common in Korea and Taiwan.”
BackgroundSmith, R. L., Haslemo, T., Andreassen, O. A., Eliasson, E., Dahl, M., Spigset, O., & Molden, E. (2017) · CNS Drugs · doi:10.1007/s40263-017-0469-1 · Cited by 23
“They summarized existing evidence for the various theories behind the toxicity, which comprised both a potential direct effect of reactive (unstable) nitrenium ion metabolite(s) and an indirect immune-mediated response [11].”
BackgroundGarg, V. K., Buttar, H. S., Bhat, S. A., Ainur, N., Priya, T., Kashyap, D., & Tuli, H. S. (2023) · Recent Advances in Inflammation & Allergy Drug Discovery · doi:10.2174/2772270817666230821102441 · Cited by 22
Paisansinsup, T., Breitenstein, M. K., & Schousboe, J. T. (2013) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e31829372e6 · Cited by 22
Nguyen, D. V., Vidal, C., Chu, H. C., & van Nunen, S. (2019) · Asia Pacific Allergy · doi:10.5415/apallergy.2019.9.e20 · Cited by 22
“This strong association has also been reported across European populations [61, 98, 99].”
BackgroundMayorga, C., Fernández‐Santamaría, R., Çelík, G., Labella, M., Murdaca, G., Sokołowska, M., Naisbitt, D. J., & Sabato, V. (2025) · Allergy · doi:10.1111/all.16576 · Cited by 21
Metadata
- Authors
- Lonjou, C., Borot, N., Sekula, P., Ledger, N., Thomas, L., Halevy, S., Naldi, L., Bouwes-Bavinck, J.-N., Sidoroff, A., de Toma, C., Schumacher, M., Roujeau, J.-C., Hovnanian, A., & Mockenhaupt, M.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- University Medical Center Freiburg (DE)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Ben-Gurion University of the Negev (IL)
- University of Milan (IT)
- Leiden University Medical Center (NL)
- Innsbruck Medical University (AT)
- Université Paris-Est Créteil (FR)
- Corresponding author
- Roujeau, Jean-Claude
- Venue
- Pharmacogenetics and Genomics
- Published
- 2008-02
- Volume
- 18
- Issue
- 2
- Pages
- 99-107
- ISSN
- 1744-6872 (ISSN-L)
- OpenAlex
- W2025161685
- Cited by
- 624
- References
- 28
- Citations by year
- 2026: 14 · 2025: 22 · 2024: 23 · 2023: 26 · 2022: 29 · 2021: 34 · 2020: 23 · 2019: 31 · 2018: 36 · 2017: 40 · 2016: 26 · 2015: 48 · 2014: 43 · 2013: 43 · 2012: 40
- FWCI
- 33.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacogenetics and Genomics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- Stevens-Johnson syndrome, toxic epidermal necrolysis, HLA-B*58:01, HLA-B*15:02, allopurinol, sulfamethoxazole, lamotrigine, oxicams, drug-induced skin reaction, European populations, genetic susceptibility
- MeSH terms
- Adult, Aged, Base Sequence, Female, Humans, Male, Middle Aged, Stevens-Johnson Syndrome, HLA-B Antigens, DNA Primers, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.